SGMO Relative Valuation
SGMO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SGMO is overvalued; if below, it's undervalued.
Historical Valuation
Sangamo Therapeutics Inc (SGMO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.36. The fair price of Sangamo Therapeutics Inc (SGMO) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：0.50
Fair
-2.47
PE
1Y
3Y
5Y
Trailing
Forward
-2.26
EV/EBITDA
Sangamo Therapeutics Inc. (SGMO) has a current EV/EBITDA of -2.26. The 5-year average EV/EBITDA is 1.11. The thresholds are as follows: Strongly Undervalued below -51.30, Undervalued between -51.30 and -25.09, Fairly Valued between 27.31 and -25.09, Overvalued between 27.31 and 53.52, and Strongly Overvalued above 53.52. The current Forward EV/EBITDA of -2.26 falls within the Historic Trend Line -Fairly Valued range.
-5.03
EV/EBIT
Sangamo Therapeutics Inc. (SGMO) has a current EV/EBIT of -5.03. The 5-year average EV/EBIT is -2.53. The thresholds are as follows: Strongly Undervalued below -7.47, Undervalued between -7.47 and -5.00, Fairly Valued between -0.06 and -5.00, Overvalued between -0.06 and 2.41, and Strongly Overvalued above 2.41. The current Forward EV/EBIT of -5.03 falls within the Undervalued range.
1.60
PS
Sangamo Therapeutics Inc. (SGMO) has a current PS of 1.60. The 5-year average PS is 6.49. The thresholds are as follows: Strongly Undervalued below -3.72, Undervalued between -3.72 and 1.39, Fairly Valued between 11.60 and 1.39, Overvalued between 11.60 and 16.70, and Strongly Overvalued above 16.70. The current Forward PS of 1.60 falls within the Historic Trend Line -Fairly Valued range.
-3.21
P/OCF
Sangamo Therapeutics Inc. (SGMO) has a current P/OCF of -3.21. The 5-year average P/OCF is -4.41. The thresholds are as follows: Strongly Undervalued below -10.95, Undervalued between -10.95 and -7.68, Fairly Valued between -1.14 and -7.68, Overvalued between -1.14 and 2.13, and Strongly Overvalued above 2.13. The current Forward P/OCF of -3.21 falls within the Historic Trend Line -Fairly Valued range.
-2.78
P/FCF
Sangamo Therapeutics Inc. (SGMO) has a current P/FCF of -2.78. The 5-year average P/FCF is -4.48. The thresholds are as follows: Strongly Undervalued below -15.90, Undervalued between -15.90 and -10.19, Fairly Valued between 1.23 and -10.19, Overvalued between 1.23 and 6.94, and Strongly Overvalued above 6.94. The current Forward P/FCF of -2.78 falls within the Historic Trend Line -Fairly Valued range.
Sangamo Therapeutics Inc (SGMO) has a current Price-to-Book (P/B) ratio of 25.75. Compared to its 3-year average P/B ratio of 6.79 , the current P/B ratio is approximately 279.13% higher. Relative to its 5-year average P/B ratio of 5.20, the current P/B ratio is about 394.87% higher. Sangamo Therapeutics Inc (SGMO) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -116.70%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -76.14% , the current FCF yield is about -100.00% lower.
27.34
P/B
Median3y
6.79
Median5y
5.20
-45.47
FCF Yield
Median3y
-116.70
Median5y
-76.14
Competitors Valuation Multiple
The average P/S ratio for SGMO's competitors is 0.00, providing a benchmark for relative valuation. Sangamo Therapeutics Inc Corp (SGMO) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -98.82%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SGMO decreased by 48.03% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from 0.00 to -1.19.
The secondary factor is the Revenue Growth, contributed -98.82%to the performance.
Overall, the performance of SGMO in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Sangamo Therapeutics Inc (SGMO) currently overvalued or undervalued?
What is Sangamo Therapeutics Inc (SGMO) fair value?
How does SGMO's valuation metrics compare to the industry average?
What is the current P/B ratio for Sangamo Therapeutics Inc (SGMO) as of Dec 05 2025?
What is the current FCF Yield for Sangamo Therapeutics Inc (SGMO) as of Dec 05 2025?
What is the current Forward P/E ratio for Sangamo Therapeutics Inc (SGMO) as of Dec 05 2025?